Condition

Metastatic Hormone-sensitive Prostate Cancer (mHSPC) clinical trials and research

• 12Clinical trials
• 25Countries

Newest Metastatic Hormone-sensitive Prostate Cancer (mHSPC) clinical trials

All recruiting trials (12)

• Saruparib plus physician’s ARPI choice vs placebo in men with metastatic hormone-sensitive prostate cancer previously treated with docetaxel or Lu-PSMA

  This study tests whether adding saruparib to a physician’s choice of ARPI helps men with metastatic hormone-sensitive prostate cancer who have already had docetaxel or Lu-PSMA therapy and no progression, compared with placebo plus ARPI.

  Recruiting at 6 sites Phase 3 AstraZeneca · Hot Springs, Arkansas and 209 other locations · NCT07711002

• PSMA-targeted therapy with hormone suppression for low-volume metastatic prostate cancer

  This phase II trial tests leuprolide acetate alone versus with 177Lu-PSMA-617 (with or without abiraterone acetate and prednisone) in men with hormone-sensitive, low-volume metastatic prostate cancer.

  Recruiting Phase 2 Mayo Clinic · Rochester, Minnesota · NCT07650240

• How darolutamide with hormone therapy works for advanced prostate cancer in German practice

  This observational study looks at how well darolutamide added to hormone therapy works for German men with metastatic hormone-sensitive prostate cancer who are already starting this combination in routine care.

  Recruiting Bayer · Locations · NCT07395804

• Rezvilutamide versus enzalutamide for low-volume metastatic hormone-sensitive prostate cancer

  This Phase III trial tests whether rezvilutamide works as well as or better than enzalutamide for men with low-volume metastatic hormone-sensitive prostate cancer who are receiving androgen-deprivation therapy.

  Recruiting Phase 3 Jiangsu HengRui Medicine Co., Ltd. · Beijing, Beijing Municipality · NCT07241416

• PSA‑triggered intermittent relugolix plus ARPI for metastatic hormone‑sensitive prostate cancer

  This trial will test whether taking relugolix with an androgen receptor pathway inhibitor on an intermittent schedule based on PSA levels works for men with metastatic hormone‑sensitive prostate cancer who achieve a strong PSA response.

  Recruiting Phase 2 University of Utah · Salt Lake City, Utah · NCT07216248

• Tulmimetostat with darolutamide or abiraterone for metastatic hormone-sensitive prostate cancer

  This trial will test whether adding tulmimetostat to darolutamide or abiraterone helps men with metastatic hormone-sensitive prostate cancer control their cancer better.

  Recruiting at 30 sites Phase 1/2 Novartis · Birmingham, Alabama and 30 other locations · NCT07190300

• Adding xaluritamig to androgen receptor pathway inhibitors for metastatic hormone-sensitive prostate cancer

  This trial tests whether adding xaluritamig to darolutamide or abiraterone is safe and tolerable for men with high-volume metastatic hormone-sensitive prostate cancer who have recently started hormone therapy.

  Recruiting at 16 sites Phase 1 Amgen · San Francisco, California and 15 other locations · NCT07140900

• Registry for prostate cancer treatment and outcomes

  This study is tracking the treatment and progress of men with recurrent and advanced prostate cancer to see how different therapies affect their lives over time.

  Recruiting at 53 sites UroTrials Company (GmbH) · Freiburg im Breisgau, Baden-Wurttemberg and 52 other locations · NCT06835218

• Observing the safety and effectiveness of darolutamide with hormone therapy and chemotherapy for Japanese men with low-volume metastatic prostate cancer

  This study looks at how safe and effective a combination of darolutamide, hormone therapy, and chemotherapy is for Japanese men with low-volume metastatic prostate cancer.

  Recruiting Bayer · Many Locations · NCT06661122

• Comparing short-term and long-term treatment options for advanced prostate cancer

  This study is testing if a shorter 6-month treatment with Rezvilutamide and hormone therapy works just as well as a longer treatment for men with advanced prostate cancer.

  Recruiting Phase 3 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT05956639

• Combination treatment for metastatic hormone-sensitive prostate cancer

  This study is testing whether adding local treatment like radiation or surgery to a hormone therapy for prostate cancer helps patients live longer without their cancer getting worse.

  Recruiting Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Milan, Lombardy and 2 other locations · NCT05649943

• Biomarker-driven treatment for metastatic prostate cancer

  This study is testing if personalized treatments based on specific genetic markers can help people with advanced prostate cancer feel better compared to standard care.

  Recruiting at 29 sites Phase 3 Karolinska Institutet · Aalst and 31 other locations · NCT03903835

Related topics

Quick answers

How many Metastatic Hormone-sensitive Prostate Cancer (mHSPC) clinical trials are recruiting right now?

12, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 25 countries. The most sites are in United States (5 trials), Germany (4 trials), China (4 trials), Italy (3 trials), Switzerland (3 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 3: 4, Phase 2: 2, Phase 1/2: 1, Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →